Research study Program year 2020 Source: CMS Open Payments

Phase 2b SLE Dose-Finding

Research payments

$639,780

116 payments

Through program year 2020, $639,780 in research payments was reported against Phase 2b SLE Dose-Finding, across 116 payments, paid by Amgen Inc..

Paid by: Amgen Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$539,950	86
2019	Research	$99,830	30

Breakdown

Who paid Research payments · program years 2019–2020

Amgen Inc. $639,780 116 payments

Who received the money Research payments · program years 2019–2020

The Oklahoma Center For Arthritis Therapy And Research INC Organisation paid for research $39,607 4 payments
University Of Colorado Denver Organisation paid for research $33,902 3 payments
Djl Clinical Research Pllc Organisation paid for research $31,171 4 payments
Joint And Muscle Research Institute Organisation paid for research $30,339 4 payments
Feinstein Institute for Medical Research Organisation paid for research $29,599 5 payments
Imaging Endpoints Organisation paid for research $28,901 2 payments
Articularis Healthcare Group INC Dba Low Country Rheumatology Organisation paid for research $25,218 3 payments
Piedmont Healthcare Organisation paid for research $25,205 3 payments
Piedmont Atlanta Hospital Organisation paid for research $24,080 3 payments
Clinic Of Robert Hozman - Cis Organisation paid for research $23,055 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.